English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis
The Journal of Dermatology · 2023
DOI: 10.1111/1346-8138.16797 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Hidehisa Saeki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Janus Kinase Inhibitors, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
This is the English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 and tyrosine kinase 2 [TYK2] inhibitors) in the treatments of psoriasis. Several cytokines, such as interleukin (IL)‐6, IL‐7, IL‐12, IL‐21, IL‐22, IL‐23, interferon (IFN)‐α, and IFN‐γ, are involved in the pathogenesis of psoriasis (including psoriatic arthritis). As oral JAK inhibitors hinder the JAK‐signal transducers and activators of transcription signal transduction routes involved in the signal transduction of these cytokines, they may be effective for the treatment of psoriasis. JAK has four types: JAK1, JAK2, JAK3, and TYK2. Regarding the use of oral JAK inhibitors for the treatment of psoriasis in Japan, indications of the JAK1 inhibitor upadacitinib were extended also to psoriatic arthritis in 2021, and the use of the TYK2 inhibitor deucravacitinib for plaque‐type psoriasis, pustular psoriasis, and erythrodermic psoriasis became covered by health insurance in 2022. This guidance was developed for board‐certified dermatologists who specialize in the treatment of psoriasis and to promote the proper use of oral JAK inhibitors. In the package inserts and guides for appropriate use, upadacitinib and deucravacitinib are classified as a “JAK inhibitor” and a “TYK2 inhibitor”, respectively, and it is possible that there may be differences in safety between the two drugs. The safety of these drugs will be evaluated for the future by the postmarketing surveillance for molecularly targeted drugs for psoriasis of the Japanese Dermatological Association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Department of Dermatology, Tokai University School of Medicine, Isehara, Japan.
- Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
- Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
- Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.
- Department of Dermatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
ORCID-Profile: Hidehisa Saeki, Akihiko Asahina, Shinichi Imafuku, Yukari Okubo, Mayumi Komine, Hideshi Torii, Akimichi Morita
Zitieren
APA
Saeki, H., Mabuchi, T., Asahina, A., Abe, M., Igarashi, A., Imafuku, S., Okubo, Y., Komine, M., Takahashi, K., Torii, H., Morita, A., Yotsuyanagi, H., Watanabe, A., Ohtsuki, M., & Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association (2023). English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16797
Vancouver
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, et al. English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16797
BibTeX
@article{Saeki2023,
author = {Saeki, Hidehisa and Mabuchi, Tomotaka and Asahina, Akihiko and Abe, Masatoshi and Igarashi, Atsuyuki and Imafuku, Shinichi and Okubo, Yukari and Komine, Mayumi and Takahashi, Kenzo and Torii, Hideshi and Morita, Akimichi and Yotsuyanagi, Hiroshi and Watanabe, Akira and Ohtsuki, Mamitaro and Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association, Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association},
title = {English version of Japanese guidance for the use of oral Janus kinase inhibitors ( JAK1 and TYK2 inhibitors) in the treatments of psoriasis},
journal = {The Journal of Dermatology},
year = {2023},
doi = {10.1111/1346-8138.16797}
}
EUVIMED